Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Giraldo NA, Peske JD, Sautès-Fridman C, Fridman WH.

Virchows Arch. 2019 Jan 10. doi: 10.1007/s00428-018-02517-1. [Epub ahead of print] Review.

PMID:
30631935
2.

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, Salkova E, Rob L, Kodet R, Goc J, Sautes-Fridman C, Fridman WH, Ryska A, Galluzzi L, Spisek R, Fucikova J.

J Immunother Cancer. 2018 Dec 4;6(1):139. doi: 10.1186/s40425-018-0446-3.

3.

The clinical role of the TME in solid cancer.

Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C.

Br J Cancer. 2019 Jan;120(1):45-53. doi: 10.1038/s41416-018-0327-z. Epub 2018 Nov 9. Review.

PMID:
30413828
4.

Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine.

Petitprez F, Sun CM, Lacroix L, Sautès-Fridman C, de Reyniès A, Fridman WH.

Front Oncol. 2018 Sep 25;8:390. doi: 10.3389/fonc.2018.00390. eCollection 2018. Review.

5.

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C.

Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12.

PMID:
30315348
6.

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, Luciani A, Amaddeo G, Derman J, Charpy C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C.

J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.

PMID:
30213589
7.

Immune-based identification of cancer patients at high risk of progression.

Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautès-Fridman C.

Curr Opin Immunol. 2018 Apr;51:97-102. doi: 10.1016/j.coi.2018.03.005. Epub 2018 Mar 16. Review.

PMID:
29554496
8.

Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum.

Yagi H, Takakura D, Roumenina LT, Fridman WH, Sautès-Fridman C, Kawasaki N, Kato K.

Sci Rep. 2018 Feb 9;8(1):2719. doi: 10.1038/s41598-018-21145-y.

9.

[The complement system: a double edge sword in tumor progression].

Daugan M, Noe R, Herman Fridman W, Sautes-Fridman C, Roumenina LT.

Med Sci (Paris). 2017 Oct;33(10):871-877. doi: 10.1051/medsci/20173310019. Epub 2017 Oct 10. Review. French.

10.

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.

Petitprez F, Vano YA, Becht E, Giraldo NA, de Reyniès A, Sautès-Fridman C, Fridman WH.

Cancer Immunol Immunother. 2018 Jun;67(6):981-988. doi: 10.1007/s00262-017-2058-z. Epub 2017 Sep 7. Review.

PMID:
28884365
11.

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.

Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M.

Eur Urol Focus. 2017 Jun 21. pii: S2405-4569(17)30151-7. doi: 10.1016/j.euf.2017.05.013. [Epub ahead of print]

PMID:
28753812
12.

The immune contexture in cancer prognosis and treatment.

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G.

Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. doi: 10.1038/nrclinonc.2017.101. Epub 2017 Jul 25. Review.

PMID:
28741618
13.

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17.

14.

Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Dec 1;17(1):249. No abstract available.

15.

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Oct 20;17(1):218. Erratum in: Genome Biol. 2016 Dec 1;17 (1):249.

16.

Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.

Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC.

Front Immunol. 2016 Oct 3;7:407. eCollection 2016. Review.

17.

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models.

Cosette J, Ben Abdelwahed R, Donnou-Triffault S, Sautès-Fridman C, Flaud P, Fisson S.

J Vis Exp. 2016 Jul 7;(113). doi: 10.3791/53609.

18.

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.

Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C.

Immunol Rev. 2016 May;271(1):260-75. doi: 10.1111/imr.12405. Review.

PMID:
27088920
19.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

20.

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.

Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH.

Clin Cancer Res. 2016 Aug 15;22(16):4057-66. doi: 10.1158/1078-0432.CCR-15-2879. Epub 2016 Mar 18.

21.

Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.

Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Adv Immunol. 2016;130:95-190. doi: 10.1016/bs.ai.2015.12.002. Epub 2016 Jan 29. Review.

PMID:
26923001
22.

Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I.

Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3.

23.

Cancer immune contexture and immunotherapy.

Becht E, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Curr Opin Immunol. 2016 Apr;39:7-13. doi: 10.1016/j.coi.2015.11.009. Epub 2015 Dec 17. Review.

PMID:
26708937
24.

TLS in Tumors: What Lies Within.

Sautès-Fridman C, Fridman WH.

Trends Immunol. 2016 Jan;37(1):1-2. doi: 10.1016/j.it.2015.12.001. Epub 2015 Dec 17.

PMID:
26706045
25.

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH.

Oncoimmunology. 2015 Aug 7;4(12):e1049804. eCollection 2015 Dec.

26.

Trial watch: Naked and vectored DNA-based anticancer vaccines.

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Apr 2;4(5):e1026531. eCollection 2015 May.

27.

Trial Watch: Peptide-based anticancer vaccines.

Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Jan 9;4(4):e974411. eCollection 2015 Apr. Review.

28.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008866. eCollection 2015 Apr. Review.

29.

Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling.

Monteiro-Sepulveda M, Touch S, Mendes-Sá C, André S, Poitou C, Allatif O, Cotillard A, Fohrer-Ting H, Hubert EL, Remark R, Genser L, Tordjman J, Garbin K, Osinski C, Sautès-Fridman C, Leturque A, Clément K, Brot-Laroche E.

Cell Metab. 2015 Jul 7;22(1):113-24. doi: 10.1016/j.cmet.2015.05.020. Epub 2015 Jun 18.

30.

The immune response in cancer: from immunology to pathology to immunotherapy.

Giraldo NA, Becht E, Vano Y, Sautès-Fridman C, Fridman WH.

Virchows Arch. 2015 Aug;467(2):127-35. doi: 10.1007/s00428-015-1787-7. Epub 2015 Jun 16. Review.

PMID:
26077464
31.

Trial watch: IDO inhibitors in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 15;3(10):e957994. eCollection 2014 Nov. Review.

32.

Profiling of the three circulating monocyte subpopulations in human obesity.

Devêvre EF, Renovato-Martins M, Clément K, Sautès-Fridman C, Cremer I, Poitou C.

J Immunol. 2015 Apr 15;194(8):3917-23. doi: 10.4049/jimmunol.1402655. Epub 2015 Mar 18.

33.

Tumor Immunology, toward a Success Story?

Sautès-Fridman C.

Front Immunol. 2015 Feb 18;6:65. doi: 10.3389/fimmu.2015.00065. eCollection 2015. No abstract available.

34.

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.

Giraldo NA, Becht E, Pagès F, Skliris G, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, Lupo A, Alifano M, Damotte D, Cazes A, Triebel F, Freeman GJ, Dieu-Nosjean MC, Oudard S, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2015 Jul 1;21(13):3031-40. doi: 10.1158/1078-0432.CCR-14-2926. Epub 2015 Feb 16.

35.

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.

Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J.

Clin Cancer Res. 2015 Mar 15;21(6):1329-39. doi: 10.1158/1078-0432.CCR-14-1128. Epub 2015 Jan 12.

36.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

37.

Tertiary lymphoid structures in cancer and beyond.

Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH.

Trends Immunol. 2014 Nov;35(11):571-80. doi: 10.1016/j.it.2014.09.006. Epub 2014 Oct 22. Review.

PMID:
25443495
38.

The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Powell CA, Altorki NK, Merad M, Gnjatic S.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90. doi: 10.1164/rccm.201409-1671PP. Review.

39.

Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Ben Abdelwahed Bagga R, Donnou S, Cosette J, Sautès-Fridman C, Aouni M, Fisson S.

J Neurooncol. 2015 Jan;121(1):9-18. doi: 10.1007/s11060-014-1624-x. Epub 2014 Oct 10. Review.

PMID:
25300908
40.

Shaping of an effective immune microenvironment to and by cancer cells.

Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Cancer Immunol Immunother. 2014 Oct;63(10):991-7. doi: 10.1007/s00262-014-1590-3. Epub 2014 Aug 12. Review.

PMID:
25112529
41.

Trial Watch: Toll-like receptor agonists in oncological indications.

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Aug 1;3:e29179. eCollection 2014.

42.

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses.

Goc J, Fridman WH, Hammond SA, Sautès-Fridman C, Dieu-Nosjean MC.

Oncoimmunology. 2014 May 29;3:e28976. eCollection 2014.

43.

TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer.

Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, Younes M, Dieu-Nosjean MC, Fridman WH, Sautès-Fridman C, Cremer I.

Cancer Res. 2014 Sep 15;74(18):5008-18. doi: 10.1158/0008-5472.CAN-13-2698. Epub 2014 Jul 29.

44.

The immune microenvironment: a major player in human cancers.

Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C.

Int Arch Allergy Immunol. 2014;164(1):13-26. doi: 10.1159/000362332. Epub 2014 May 13. Review.

PMID:
24852691
45.

[The tumoral microenvironment: feeding resources, battle field and therapeutic target in cancer].

Fridman WH, Sautès-Fridman C.

Med Sci (Paris). 2014 Apr;30(4):359-65. doi: 10.1051/medsci/20143004007. Epub 2014 May 5. Review. French.

46.

Trial Watch: Chemotherapy with immunogenic cell death inducers.

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e27878. Epub 2014 Mar 1. Review.

47.

The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.

Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, Charpentier MC, Bain S, Marmey B, Bonjour P, Biton J, Cremer I, Dieu-Nosjean MC, Sautès-Fridman C, Régnard JF, Laurent-Puig P, Alifano M, Damotte D.

Chest. 2014 Sep;146(3):633-643. doi: 10.1378/chest.13-2499.

PMID:
24676429
48.

EFIS: driving women's representation in immunology in Europe.

Sautés-Fridman C, Erdei A.

Eur J Immunol. 2014 Mar;44(3):615. doi: 10.1002/eji.201470026. No abstract available.

49.

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e27048. Review.

50.

Characteristics of tertiary lymphoid structures in primary cancers.

Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Oncoimmunology. 2013 Dec 1;2(12):e26836. Epub 2013 Oct 22. Review.

Supplemental Content

Loading ...
Support Center